MTOR and neoplasm: Previously, we have demonstrated that Urolithin A mediated simultaneous targeting of the PI3K/Akt/mTOR pathway reduced PDAC tumor growth and improved survival in the genetically engineered mouse model (GEMM) of PDAC [15].